# Damien Tappy

> Damien Tappy is a Series C investor at Endeavour Vision backing Medical Device and Health Care. See 6 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Endeavour Vision](https://shizune.co/investors/profile/endeavour-vision)
- Location: Geneva, Switzerland
- Total investments: 6
- Last investment: Apr 2021
- Lead investor: 50%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/damientappy

Damien Tappy is a Series C investor at Endeavour Vision in Geneva focused on Medical Device and Health Care. Damien Tappy - President & Managing Partner @ Endeavour Vision

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical Device | 4 | 67% |
| Health Care | 3 | 50% |
| Medical | 2 | 33% |
| Biotechnology | 2 | 33% |
| Delivery | 1 | 17% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 2 | 33% |
| Series A | 1 | 17% |
| Series D | 1 | 17% |
| Funding Round | 1 | 17% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 2 | 33% |
| Romania | 1 | 17% |
| Switzerland | 1 | 17% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| CeQur | CeQur SA is dedicated to developing and commercializing advanced insulin delivery systems that make it easier for people living with type 2 diabetes to comply with therapy and stay in control of their disease.CeQur is developing the CeQurâ„¢ Insulin Infuser, a simple and discrete insulin delivery tool for people who could benefit from intensiveinsulin therapy but want flexibility and freedom from multiple daily injections.CeQur was established in January 2008 as a spin out from Danfoss A/S, a large, global Danish industrial products group. The company is headquartered in Montreux, Switzerland, with operations in Nordborg, Denmark and Marlborough, Massachusetts. | $115M | Series C | Apr 13, 2021 |  |
| VertiFlex | VertiFlex, Inc., a medical device company, provides minimally invasive and motion preserving spinal surgery technologies in the United States and internationally. The company offers superion interspinous spacer, a percutaneous titanium implant that fits between the spinous processes in the lumbar spine. Its Superion is a motion-preservinginterspinous spacer for the treatment of moderate spinal stenosis.Vertiflex Inc was founded in 2005 and is headquartered in California, USA. | $45.3M |  | Mar 27, 2017 |  |
| EndoStim | EndoStim is a medical device company developing therapeutics for gastrointestinal and urological neuro-muscular disorders. It is performing clinical trials to pursue FDA approval for a new treatment for sphincter-related disorders such as gastroesophageal reflux disease (GERD) and urinary urge incontinence. Its microstimulator technology provideslong-term reflux control by restoring normal esophageal function that directly targets the patient's weak or dysfunctional lower esophageal sphincter (LES) muscle between the stomach and the esophagus and enable patients to reduce or avoid typical gastrointestinal side effects of traditional anti-reflux surgery. | $25M | Series D | May 12, 2016 |  |
| CeQur | CeQur SA is dedicated to developing and commercializing advanced insulin delivery systems that make it easier for people living with type 2 diabetes to comply with therapy and stay in control of their disease.CeQur is developing the CeQurâ„¢ Insulin Infuser, a simple and discrete insulin delivery tool for people who could benefit from intensiveinsulin therapy but want flexibility and freedom from multiple daily injections.CeQur was established in January 2008 as a spin out from Danfoss A/S, a large, global Danish industrial products group. The company is headquartered in Montreux, Switzerland, with operations in Nordborg, Denmark and Marlborough, Massachusetts. | $100M | Series C | Sep 01, 2015 |  |
| CeQur | CeQur SA is dedicated to developing and commercializing advanced insulin delivery systems that make it easier for people living with type 2 diabetes to comply with therapy and stay in control of their disease.CeQur is developing the CeQurâ„¢ Insulin Infuser, a simple and discrete insulin delivery tool for people who could benefit from intensiveinsulin therapy but want flexibility and freedom from multiple daily injections.CeQur was established in January 2008 as a spin out from Danfoss A/S, a large, global Danish industrial products group. The company is headquartered in Montreux, Switzerland, with operations in Nordborg, Denmark and Marlborough, Massachusetts. | $29.6M | Series A | Jan 05, 2010 |  |
| EndoArt | EndoArt SA |  | Series C | Mar 01, 2006 |  |

6 of 6 investments shown.

## Co-investors
- [Schroders](https://shizune.co/investors/profile/schroders-plc) — VC Fund, 3 deals together
- [VI Partners](https://shizune.co/investors/profile/vi-partners) — VC Fund, 3 deals together
- [Credit Suisse Entrepreneur Capital](https://shizune.co/investors/profile/credit-suisse-entrepreneur-capital) — VC Fund, 1 deal together
- [Federated Kaufmann Fund](https://shizune.co/investors/profile/federated-kaufmann-fund-2) — VC Fund, 1 deal together
- [Gimv](https://shizune.co/investors/profile/gimv) — VC Fund, 1 deal together
- [GMS Capital Partners](https://shizune.co/investors/profile/gms-capital-partners) — VC Fund, 1 deal together

## About Endeavour Vision

VC Fund · Geneva, Switzerland

Endeavour Vision is a private equity firm investing in growth-stage MedTech and digital health companies. The company invests in medical innovation that provides superior clinical benefits for patients or brings significant efficiencies to health systems. Endeavour Vision team offers strategic and operational expertise and extensive internationalexperience investing in companies in Europe and North America. We have a proven track record of successful exits with recently realized investments that include Vertiflex (acquired by Boston Scientific in 2019), Medartis (IPO on SIX in Q1 2018), and Symetis (acquired by Boston Scientific in 2017). Endeavour Vision’s offices are located in Geneva, Switzerland, and Minneapolis, U.S.

5 contacts available at Endeavour Vision.

| Name | Title | Profile |
| --- | --- | --- |
| Alex Schmitz | Partner | https://shizune.co/investors/profile/alex-schmitz-2 |
| Bernard Vogel | Founder and Managing Partner | https://shizune.co/investors/profile/bernard-vogel |
| Damien Tappy | President & Managing Partner | https://shizune.co/investors/profile/damien-tappy |
| Daniel van den Bergh | Senior Investment Director | https://shizune.co/investors/profile/daniel-van-den-bergh |
| Fernando Pacheco | Investment Director | https://shizune.co/investors/profile/fernando-pacheco |

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does Damien Tappy invest in?

Damien Tappy invests primarily in Medical Device, Health Care and Medical startups, most often at Series C and Series A stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Damien Tappy last invest?

The most recent investment recorded for Damien Tappy closed in Apr 2021. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co